|Bid||366.40 x 0|
|Ask||366.60 x 0|
|Day's Range||360.10 - 367.60|
|52 Week Range||212.70 - 413.20|
|PE Ratio (TTM)||36.45|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
The Israel-based drugmaker on Monday tapped Kare Schultz as its new CEO. Schultz, who hails from Denmark-based Lundbeck, succeeds Dr. Yitzhak Peterburg, who has served as interim CEO since February.
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Teva Pharmaceutical Industries named Kare Schultz as its new chief executive, ending months of speculation over who will lead the Israeli drug company.